KUALA LUMPUR: Ipoh-based pharmaceutical company Hovid Bhd is in “expansion mode” now. It is investing up to RM60 million for a new research and development (R&D) centre and to expand its manufacturing facility, after which it expects to reap the fruits of its investments by the financial year ending June 30, 2018 (FY18).
Hovid, which derives 55% of its revenue from the export markets, with Asia being its biggest outbound market, is pushing for more exports.
But its plan to globally market its Tocovid Suprabio product, which is touted to be able to reduce the risk of a mini stroke, is yet to be realised, as the US FDA trials for the product are still ongoing and will need another two years before the results can be published, said Hovid’s spokesperson.
– Read the full article on The Edge –


